Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Last updated: 2026-02-04 01:19:44 ET
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration’s ...
These are the stocks posting the largest moves in early trading.